Ocugen Advances Gene Therapy Pipeline as Phase 3 Trials Near Key Milestones
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) reported third-quarter 2025 financial results and provided an update on its advancing portfolio of late-stage gene therapies for inherited retinal diseases. The biotechnology …
Ocugen Advances Gene Therapy Pipeline as Phase 3 Trials Near Key Milestones Read More